Clinical Trial

Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients

Study acronym: ADDIT-GLIO
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
In this phase I/II trial, the primary objective is to determine overall and progression-free survival of patients with newly diagnosed glioblastoma when autologous Wilms' tumor 1 (WT1) messenger (m)RNA-loaded dendritic cell (DC) vaccination is added to adjuvant temozolomide maintenance treatment following (sub)total resection and temozolomide-based chemoradiation.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2016-01-05; most recent amendment 2026-06-03.
Status change: Recruiting → Active, Not Recruiting 2024-09-12
Trial Details
NCT Number NCT02649582
Lead Sponsor University Hospital, Antwerp
Conditions Glioblastoma Multiforme of Brain
Enrollment 20 participants
Start Date 2015-12
Primary Completion 2027-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-06-04